(FFN) Ciencias Farmacéuticas
Departamento académico
Universidad del País Vasco/Euskal Herriko Unibertsitatea
Lejona, EspañaPublicaciones en colaboración con investigadores/as de Universidad del País Vasco/Euskal Herriko Unibertsitatea (32)
2024
-
Astrocytic GLUT1 reduction paradoxically improves central and peripheral glucose homeostasis
Science Advances , Vol. 10, Núm. 42
2023
2021
-
Transfer of SCN1A to the brain of adolescent mouse model of Dravet syndrome improves epileptic, motor, and behavioral manifestations
Molecular Therapy - Nucleic Acids, Vol. 25, pp. 585-602
2020
-
Cells, Materials, and Fabrication Processes for Cardiac Tissue Engineering
Frontiers in Bioengineering and Biotechnology, Vol. 8
2019
-
Preclinical safety of topically administered nanostructure lipid carriers (NLC) for wound healing application: biodistribution and toxicity studies
International Journal of Pharmaceutics, Vol. 569
2018
-
Plasma rich in growth factors membrane as coadjuvant treatment in the surgery of ocular surface disorders
Medicine (United States), Vol. 97, Núm. 17
2017
-
Autologous method for ex vivo expansion of human limbal epithelial progenitor cells based on plasma rich in growth factors technology
Ocular Surface, Vol. 15, Núm. 2, pp. 248-256
-
The Use of Fluoroproline in MUC1 Antigen Enables Efficient Detection of Antibodies in Patients with Prostate Cancer
Journal of the American Chemical Society, Vol. 139, Núm. 50, pp. 18255-18261
2015
-
Population pharmacokinetic models for cefuroxime and metronidazole used in combination as prophylactic agents in colorectal surgery: Model-based evaluation of standard dosing regimens
International Journal of Antimicrobial Agents, Vol. 45, Núm. 5, pp. 504-511
2014
-
Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: Application to pharmacokinetic/pharmacodynamic analysis
Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 1, pp. 180-189
2012
-
Long lasting effects of early-life stress on glutamatergic/GABAergic circuitry in the rat hippocampus
Neuropharmacology, Vol. 62, Núm. 5-6, pp. 1944-1953
-
Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery
European Journal of Clinical Pharmacology, Vol. 68, Núm. 5, pp. 735-745
2011
-
Pharmacokinetic/pharmacodynamic evaluation of amoxicillin, amoxicillin/clavulanate and ceftriaxone in the treatment of paediatric acute otitis media in Spain
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 29, Núm. 3, pp. 167-173
2010
-
A semi-physiological-based pharmacokinetic/pharmacodynamic model to describe the effects of topotecan on B-lymphocyte lineage cells
Pharmaceutical Research, Vol. 27, Núm. 3, pp. 431-441
2008
-
Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy
Clinical Pharmacokinetics, Vol. 47, Núm. 3, pp. 173-180
2000
-
Alpha1-acid glycoprotein (AAG) and serum protein binding of methadone in heroin addicts with abstinence syndrome
International Journal of Clinical Pharmacology and Therapeutics, Vol. 38, Núm. 1, pp. 35-40
-
Modeling of the in vivo antinociceptive interaction between an opioid agonist, (+)-O-desmethyltramadol, and a monoamine reuptake inhibitor, (-)-O-desmethyltramadol, in rats
Journal of Pharmacology and Experimental Therapeutics, Vol. 295, Núm. 1, pp. 352-359
-
Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effects of main active metabolites of tramadol, (+)-O-desmethyltramadol and (-)-O- desmethyltramadol, in rats
Journal of Pharmacology and Experimental Therapeutics, Vol. 293, Núm. 2, pp. 646-653
-
Pharmacokinetic-pharmacodynamic modelling of the antipyretic effect of two oral formulations of ibuprofen
Clinical Pharmacokinetics, Vol. 38, Núm. 6, pp. 505-518
1999
-
Altered plasma and brain disposition and pharmacodynamics of methadone in abstinent rats
Journal of Pharmacology and Experimental Therapeutics, Vol. 288, Núm. 1, pp. 179-187